Search research articles
Contact Us
Filters
Showing results (21-30 of 29) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 29 results.
Cancer
|
October 1, 1991
Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha
J A Sparano, J P Dutcher, R Kaleya, et al.
Journal of Clinical Immunology
|
October 1, 1983
Defective T-cell response to PHA and mitogenic monoclonal antibodies in male homosexuals with acquired immunodeficiency syndrome and its in vitro correction by interleukin 2
N Ciobanu, K Welte, G Kruger, et al.
The American Journal of Clinical Nutrition
|
December 1, 1991
Hypovitaminosis C in patients treated with high-dose interleukin 2 and lymphokine-activated killer cells
S L Marcus, D P Petrylak, J P Dutcher, et al.
Seminars in Oncology
|
August 1, 1993
Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies
P Crilley, H Lazarus, D Topolsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1989
A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma
J P Dutcher, S Creekmore, G R Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1992
High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma
H M Lazarus, P Crilley, N Ciobanu, et al.
Blood
|
November 1, 1993
Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques
A A Ross, B W Cooper, H M Lazarus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1990
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells
M H Bar, M Sznol, M B Atkins, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy
|
June 1, 1991
Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma
K A Margolin, F R Aronson, M Sznol, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 29) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 29 results.
Cancer
|
October 1, 1991
Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha
J A Sparano, J P Dutcher, R Kaleya, et al.
Journal of Clinical Immunology
|
October 1, 1983
Defective T-cell response to PHA and mitogenic monoclonal antibodies in male homosexuals with acquired immunodeficiency syndrome and its in vitro correction by interleukin 2
N Ciobanu, K Welte, G Kruger, et al.
The American Journal of Clinical Nutrition
|
December 1, 1991
Hypovitaminosis C in patients treated with high-dose interleukin 2 and lymphokine-activated killer cells
S L Marcus, D P Petrylak, J P Dutcher, et al.
Seminars in Oncology
|
August 1, 1993
Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies
P Crilley, H Lazarus, D Topolsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1989
A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma
J P Dutcher, S Creekmore, G R Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1992
High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma
H M Lazarus, P Crilley, N Ciobanu, et al.
Blood
|
November 1, 1993
Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques
A A Ross, B W Cooper, H M Lazarus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1990
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells
M H Bar, M Sznol, M B Atkins, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy
|
June 1, 1991
Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma
K A Margolin, F R Aronson, M Sznol, et al.
Page
of 3